<DOC>
	<DOCNO>NCT01662804</DOCNO>
	<brief_summary>The purpose study find `` humanize 3F8 '' ( Hu3F8 ) combine interleukin-2 ( rIL2 ) safe treat neuroblastoma cancer . A phase 1 study mean investigator try find side effect happen high high dos drug use . The investigator want find effect , good and/or bad , Hu3F8 combine rIL2 cancer . The amount Hu3F8 patient get depend start treatment study . The amount rIL2 patient . The investigator also want find Hu3F8 work effective attack disease combine rIL2 .</brief_summary>
	<brief_title>Humanized 3F8 Monoclonal Antibody ( Hu3F8 ) When Combined With Interleukin-2 Patients With High-Risk Neuroblastoma GD2-positive Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Patients must either ( 1 ) diagnosis NB define international criteria,84 i.e. , histopathology ( confirm MSKCC Department Pathology ) BM metastases plus high urine catecholamine level , ( 2 ) tumor GD2positive . A nonNB tumor define GD2positive immunostaining m3F8 . If fresh frozen tumor available immunostaining , patient consider eligible publish report show &gt; 50 % tumor type GD2positive immunohistochemistry . ( Note : Tissues must fresh/frozen fix , paraffinembedded specimen unsuitable antiGD2 immunostaining ) . Tumors know GD2 positive criterion need immunostaining . These include : Melanoma ( &gt; 50 % ) , Desmoplastic small round cell tumor ( 70 % ) , Osteosarcoma ( 88 % ) Soft tissue sarcoma include liposarcoma , fibrosarcoma , malignant fibrous histiocytoma , leiomyosarcoma , spindle cell sarcoma ( 93 % ) . Patients must either ( 1 ) refractory relapse highrisk NB ( include MYCNamplified stage 2/3/4/4S age MYCNnonamplified stage 4 patient great 18 month age ) resistant standard therapy* , ( 2 ) refractory relapse GD2positive tumor receive available lifeprolonging therapy . *For NB , standard therapy generally include 58 cycle high dose induction chemotherapy follow resection gross residual tumor , without myeloablative chemotherapy peripheral blood stem cell rescue radiation therapy primary site . There also salvage chemotherapy regimens residual disease standard induction therapy relapse NB . Some example chemotherapy combination : highdose cyclophosphamide , topotecan vincristine ; highdose cyclophosphamide , irinotecan vincristine ; irinotecan temozolomide ; ifosfamide , carboplatin etoposide . Patients must older 1 year age . Prior treatment murine 3F8 allow . Patients prior m3F8 , hu3F8 , ch14.18 hu14.18 treatment must HAHA antibody titer le = 1300 Elisa units/ml White blood cell count ≥1000/ul Absolute neutrophil count ≥500/ul Absolute lymphocyte count ≥500/ul Platelet count ≥25,000/ul No chemotherapy immunotherapy minimum three week prior study enrollment Women childbearing potential must willing practice effective method birth control treatment Signed informed consent indicate awareness investigational nature program . Existing major organ dysfunction &gt; grade 2 , exception hearing loss hematologic toxicity ( defined suppression subtypes WBCs , RBCs , platelet ) . Hematologic primary CNS malignancy Active lifethreatening infection . Pregnant woman woman breastfeed . Inability comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>13 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>INTERLEUKIN 2</keyword>
	<keyword>MAB 3F8</keyword>
	<keyword>GD2-positive tumor</keyword>
	<keyword>12-116</keyword>
</DOC>